Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in treatments for ear, nose, and throat (ENT) and allergy patients, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's management team will deliver a presentation on September 9, 2024, at 10:00 a.m. ET, providing a comprehensive overview of the company and updates on its business operations.
Investors and interested parties can access a live webcast of the presentation through the Investors page on the Optinose website. For those unable to attend the live event, a replay of the webcast will be available for 30 days following the conference.
Optinose (NASDAQ:OPTN), un'azienda farmaceutica specializzata nel trattamento di pazienti con problemi di orecchio, naso e gola (ENT) e allergie, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale Globale sugli Investimenti H.C. Wainwright. Il team di management dell'azienda presenterà il 9 settembre 2024, alle 10:00 ET, fornendo una panoramica completa dell'azienda e aggiornamenti sulle sue operazioni commerciali.
Gli investitori e le parti interessate possono accedere a una webcasting in diretta della presentazione attraverso la pagina Investors sul sito web di Optinose. Per coloro che non possono partecipare all'evento dal vivo, sarà disponibile una registrazione della webcasting per 30 giorni dopo la conferenza.
Optinose (NASDAQ:OPTN), una compañía farmacéutica especializada en tratamientos para pacientes de oído, nariz y garganta (ENT) y alergias, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversiones H.C. Wainwright. El equipo directivo de la compañía realizará una presentación el 9 de septiembre de 2024, a las 10:00 a.m. ET, proporcionando una visión completa de la compañía y actualizaciones sobre sus operaciones comerciales.
Los inversores y partes interesadas podrán acceder a una transmisión en vivo de la presentación a través de la página de Inversores en el sitio web de Optinose. Para aquellos que no puedan asistir al evento en vivo, estará disponible una repetición de la transmisión durante 30 días después de la conferencia.
옵티노스(Optinose, NASDAQ:OPTN)는 귀, 코 및 목(ENT) 및 알레르기 환자를 위한 치료에 전문화된 제약 회사로, H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 회사의 경영진은 2024년 9월 9일 오전 10:00(ET)에 발표를 진행하여 회사에 대한 포괄적인 개요와 비즈니스 운영에 대한 업데이트를 제공할 것입니다.
투자자 및 관심 있는 당사자는 옵티노스 웹사이트의 투자자 페이지를 통해 발표의 실시간 웨비나에 접근할 수 있습니다. 실시간 이벤트에 참석할 수 없는 분들을 위해 컨퍼런스 이후 30일 동안 웨비나 재생이 제공될 예정입니다.
Optinose (NASDAQ:OPTN), une entreprise pharmaceutique spécialisée dans les traitements pour les patients atteints de problèmes d'oreilles, de nez et de gorge (ENT) ainsi que d'allergies, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'équipe de direction de l'entreprise présentera une communication le 9 septembre 2024 à 10h00 ET, offrant un aperçu complet de l'entreprise et des mises à jour sur ses opérations commerciales.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la page des investisseurs sur le site web d'Optinose. Pour ceux qui ne peuvent pas assister à l'événement en direct, un enregistrement du webinaire sera disponible pendant 30 jours après la conférence.
Optinose (NASDAQ:OPTN), ein Pharmaunternehmen, das auf Behandlungen für Patienten mit Ohren-, Nasen- und Halsproblemen (ENT) sowie Allergien spezialisiert ist, hat seine Teilnahme an der 26. jährlichen globalen Investmentkonferenz von H.C. Wainwright angekündigt. Das Management-Team des Unternehmens wird am 9. September 2024 um 10:00 Uhr ET eine Präsentation halten, die einen umfassenden Überblick über das Unternehmen und Aktualisierungen zu seinen Geschäftsabläufen bietet.
Investoren und Interessierte können über die Investoren-Seite auf der Optinose-Website auf einen Livestream der Präsentation zugreifen. Für diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, wird eine Aufzeichnung des Livestreams 30 Tage nach der Konferenz verfügbar sein.
- None.
- None.
YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 at 10:00 a.m. ET.
To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.
A replay of the webcast will be available for 30 days following the conclusion of the event.
About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn.
Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531
FAQ
When is Optinose (OPTN) presenting at the H.C. Wainwright Global Investment Conference?
How can I watch Optinose's (OPTN) presentation at the H.C. Wainwright conference?
How long will the replay of Optinose's (OPTN) presentation be available?
What is Optinose's (OPTN) focus as a pharmaceutical company?
